KXA
EPZM

KPCB XIII Associates’s Epizyme, Inc EPZM Stock Holding History

KPCB XIII Associates’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$19.7M Hold
3,838,166
– – 3.92% 4
2021
Q2 		$31.9M Hold
3,838,166
– – 5.87% 3
2021
Q1 		$33.4M Hold
3,838,166
– – 6.87% 4
2020
Q4 		$41.7M Buy
+3,838,166
New +$47.3M 6.74% 3

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KPCB XIII Associates's EPZM Position: Q3 2021 in Review

KPCB XIII Associates held its Epizyme, Inc (EPZM) position steady in Q3 2021 at 3,838,166 shares worth $19.7M. The position accounts for 3.92% of the portfolio, ranked #4.

KPCB XIII Associates first reported a position in EPZM in Q4 2020 and has held it in 4 quarters since. The position peaked at $41.7M in Q4 2020. 116 funds tracked by Wall St. Rank hold EPZM as of Q3 2021.

  • KPCB XIII Associates held 3,838,166 shares of Epizyme, Inc worth $19.7M as of Q3 2021.
  • KPCB XIII Associates left its Epizyme, Inc share count unchanged in Q3 2021.
  • Epizyme, Inc made up 3.92% of KPCB XIII Associates's portfolio in Q3 2021, its #4 holding.
  • KPCB XIII Associates first reported a position in Epizyme, Inc in Q4 2020 and has held it in 4 quarters since.
  • KPCB XIII Associates's Epizyme, Inc position peaked at $41.7M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2021.

Based on KPCB XIII Associates's 13F filing for Q3 2021, filed 25 Oct 2021.